Literature DB >> 17804901

Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.

S Kannan Ramamoorthy1, Ramesh Pandita, Ajay Prakash, N V Ramaswamy, Soad Al Bahar.   

Abstract

Acute leukemia presenting as cholestatic jaundice is rare. It can occur due to granulocytic sarcoma compressing the bile ducts in case of acute myeloid leukemia. Rarely, diffuse infiltration of the liver sinusoids by the leukemic blasts can present as cholestatic jaundice. We report a case of chronic myeloid leukemia in lymphoid blast cell crisis presenting with severe cholestatic jaundice due to diffuse infiltration of the liver sinusoids with lymphoblasts. This patient tolerated imatinib well and, coinciding with the hematological response, there was marked reduction in the cholestasis due to blast clearance from the hepatic sinusoids. He was subsequently treated with combination chemotherapy and achieved morphological and cytogenetic remission. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804901     DOI: 10.1159/000107925

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  1 in total

1.  Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.

Authors:  Muhammad Wasif Saif; Melissa Hennessey Smith; Antonia Maloney; Robert B Diasio
Journal:  Ann Gastroenterol       Date:  2016-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.